alexa Serotonin in the Frontal Cortex: A Potential Therapeutic Target for Neurological Disorders | Open Access Journals
ISSN: 2167-0501
Biochemistry & Pharmacology: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Serotonin in the Frontal Cortex: A Potential Therapeutic Target for Neurological Disorders

Hui Lu1* and Qing-song Liu2

1Department of Pharmacology and Physiology, George Washington University, Washington, DC 20037, USA

2Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

*Corresponding Author:
Hui Lu, Ph.D
Department of Pharmacology and Physiology
George Washington University, 2300 I Steet NW
Washington, DC 20037, USA
Tel: (202) 994-4166
E-mail: [email protected]

Received date: December 22, 2016; Accepted date: December 27, 2016; Published date: December 29, 2016

Citation: Lu H, Liu Q (2016) Serotonin in the Frontal Cortex: A Potential Therapeutic Target for Neurological Disorders. Biochem Pharmacol (Los Angel) 5:e184. doi: 10.4172/2167-0501.1000e184

Copyright: © 2016 Lu H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Biochemistry & Pharmacology: Open Access

Serotonin or 5-hydroxytryptamine (5-HT) is a monoamine neurotransmitter which has broad distribution in the brain. It was discovered by Erspamer and Asero in the 1950s [1]. 5-HT is synthesized in two steps, with Tryptophan Hydroxylase (TPH) as the rate-limiting enzyme [2]. First, tryptophan is converted to 5-hydroxytryptophan (5-HTP) by TPH. Second, the intermediate product, 5-HTP, is converted to 5-HT by aromatic acid decarboxylase (AADC). 5-HT is primarily degraded by the mitochondrial bound protein Monoamine Oxidase A (MAOA), leading to the generation of the metabolite, 5-hydroxyindoleacetic acid (5-HIAA). Importantly, serotonin is also a substrate for melatonin synthesis [3]. 5-HT is released from the axonal terminals of serotoninergic neurons and acts on 14 distinct receptor subtypes that are classified into 7 different families: 5-HT1 (1A, 1B, 1D, 1E, 1F), 5-HT2 (2A, 2B, and 2C), 5-HT3, 5-HT4, 5- HT5 (5A, 5B), 5-HT6, and 5-HT7. Among all these receptors, only 5-HT3 receptor is a pentameric ligand-gated ion channel composed of several subunits of which 5 different types have been identified [4]. All other 5-HT receptors are G-protein coupled receptors which regulate the activity of the neurons expressing them [5,6]. Released serotonin is transported to the presynaptic neurons by serotonin transporter (SERT or 5-HTT), a type of monoamine transporter protein [7].

Serotonergic neurons are located in the raphe nuclei [8]. While the more caudal raphe nuclei project to the Peripheral Nervous System (PNS), the neurons in the dorsal and median raphe nuclei (DRN and MRN) primarily send their projections to forebrain regions [9,10]. 5-HT is critically involved in the development of many cortices, such as somatosensory cortex and barrel cortex [11,12]. In adult brain, 5-HT neurons project to majority of cortical areas, including the entorhinal and cingulate cortices. However, of all cortical regions, the frontal lobe contains the highest density of serotonergic terminals and 5-HT receptors [13]. These studies indicate that 5-HT regulates cognitive and emotional functions that rely on frontal cortical activity.

Serotonin homeostasis in the frontal cortex is important for normal behavior. It has been shown that engaging in aggressive behavior triggers dynamic changes in frontal cortical serotonin [14]. Deviation of 5-HT homeostasis increases impulsivity [15-17]. Selective depletion of 5-HT in monkey frontal cortex impairs reversal leaning and increases perseveration (loss of cognitive flexibility) [18,19]. 5-HT in the frontal cortex also modulates attention in humans [20,21]. Given its involvement in cognition and impulsivity, 5-HT is central to our understanding of the psychopathology and treatment of psychiatric disorders such as depression, schizophrenia, Obsessive Compulsive Disorder (OCD), and autism. In all of these disorders, local abnormalities in frontal cortex structure [22], neurochemistry [23], or activation [24] have been characterized and drugs for these disorders, such as ecstasy [25] and amphetamine [26], have been shown to impair cortical 5-HT neurotransmission. Moreover, Clarke et al. [18] used a serial discrimination reversal paradigm to show that selective depletion of 5-HT in the marmoset frontal cortex produced perseverative responding to the stimulus previously paired with reward without any significant effects on either retention of a discrimination learned preoperatively or acquisition of a novel discrimination postoperatively. This result highlights the importance of prefrontal serotonin in behavioral flexibility which is highly relevant to obsessive-compulsive disorder, schizophrenia, and the cognitive sequelae of drug abuse in which perseveration is prominent. More interestingly, 5-HT is very likely to be the common neurochemical factor between depression and autism as comorbidity of these two disorders is common [27]. Indeed, selective serotonin reuptake inhibitors (SSRIs) are being increasingly used in autism, because of their role in the control of depression and aggression [27-29].

Furthermore, high-frequency electrical stimulation of the Ventral Medial Prefrontal Cortex (vmPFC) is capable of enhancing 5-HT release and restoring social approach behaviour in defeated mice [30]. Additionally, manipulating vmPFC synaptic inputs to the DRN has revealed bidirectional effects on socioaffective behaviours via direct monosynaptic excitation and indirect disynaptic inhibition of 5-HT neurons [31]. Similarly, deep brain stimulation in the vmPFC improves negative bias and symptoms of mood dysregulation in Major Depressive Disorder (MDD) patients [32]. Strikingly, these results suggest that cross-species parallels exist in regards to the roles of the frontal cortex and serotonergic systems in socioaffective responses. It has been hypothesized that the plasticity of the frontal cortex-DRN circuit that links these two systems may constitute a conserved means of encoding or expressing social avoidance behaviour across species [31]. Thus, better understanding the interaction between frontal cortex and DRN and identifying key neuroplastic events that mediate normal and pathological regulation of socioaffective functions may uncover molecular targets amenable to therapeutic intervention in the treatment of affective disorders.

Acknowledgements

This work was supported by NIH Grants R01 DA035217 and R56 MH101146.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 878
  • [From(publication date):
    February-2017 - Nov 20, 2017]
  • Breakdown by view type
  • HTML page views : 790
  • PDF downloads : 88
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords